Catalog No.: PC-49595Not For Human Use, Lab Use Only.
HB3089 (HB-3089) is a novel potent, highly specific STING agonist, dose-dependently activates interferon-stimulated gene (ISG) signaling in THP1-Dual reporter cells with EC50 of 1-10 uM.
HB3089 (HB-3089) is a novel potent, highly specific STING agonist, dose-dependently activates interferon-stimulated gene (ISG) signaling in THP1-Dual reporter cells with EC50 of 1-10 uM.
HB3089 showed comparable ability to diABZI in increasing the thermal stability of various human STING isoforms and mouse STING.
HB3089 treatment (1 uM) activated the STING downstream TBK1/IRF3 signaling in dose-dependent and time-dependent manners.
HB3089 also showed the wide activation on two major human STING isoforms, STING-R232 and STING-H232.
HB3089 induced conformational changes of ligand-binding domain of STING.
HB3089 exhibited higher anti-tumor activity than STING agonist diABZI compound 3 (Cat# PC-35785) in 4T1 breast cancer and U14 cervical cancer, significantly increased CD86+ macrophages after 72 h treatment on peripheral and tumor-infiltrated immune cells from 4T1 allograft tumors.
